Non-HDL-C
Non-HDL-C
Non-HDL-C
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
NCEP ATP III Guidelines<br />
For all patients, including patients with high TG, or Low<br />
<strong>HDL</strong>), the primary target of therapy is LDL-C.<br />
Statin is the first line therapy<br />
<strong>Non</strong> <strong>HDL</strong>-C should be a secondary target of therapy<br />
when TG > 200 mg/dl. Two approaches:<br />
- Increase the dose of LDL-lowering drug (statin)<br />
- Add fibrate or nicotinic acid<br />
If isolated low <strong>HDL</strong>, TG are < 200 mg/dl, drugs for <strong>HDL</strong><br />
raising (fibrates or nicotinic acid) can be considered in<br />
high risk patients. Niacin in the first choice<br />
Third report of NCEP expert panel of detection, evaluation and treatment of high<br />
blood cholesterol in adults (ATP III). Circulation 2002; 106: 3143-421.
Change language